MarginsXMarginsX
Home › Markets › Health Care › QGEN

Qiagen N.V. Common Shares (QGEN)

QGEN trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$49.81
-0.16% on the day
Market cap
$10.3B
Large cap
Revenue · 2025
$2.1B
+5.7% on 2024
Net income · 2025
$424.9M
20.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1015820/000101582026000018/0001015820-26-000018-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerQGEN on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryNetherlands
IPO year2026
SEC CIK0001015820
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inNetherlands

Financials · 2025

LineValue
Revenue$2.1B
Net income$424.9M
Operating income$465.9M
Net margin20.3%
Operating margin22.3%
Revenue growth+5.7%
Cash$839.0M
Total assets$6.3B
P/E (computed)24.2×
P/S (computed)4.9×

Warning signs

Cash runway
Cash-flow positive
$839.0M cash at December 31, 2025
Share count, 1 year
-2.4%
2024-12-31 to 2025-12-31 · -4.7% over 3 years
Going-concern doubt
No
20-F filed March 20, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-20
Cash and burn$839.0M cash; operating cash flow $163.6M a quarter.Report 2025-12-31
Shares outstanding216,920,735 (2025-12-31); 222,290,848 a year earlier; 227,716,433 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE/A filed25-NSE/A 2026-01-09
AuditorEY GmbH & Co. KG Wirtschaftspruefungsgesellschaft, Cologne, GermanyPCAOB Form AP 2026-04-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$2.1B$424.9M$654.3M$839.0M$1.7B$2.1B20-F 2026-03-20
FY 2024
2024-12-31
$2.0B$83.6M$673.6M$663.6M$1.4B$2.0B20-F 2026-03-20
FY 2023
2023-12-31
$2.0B$341.3M$459.5M$668.1M$1.5B$2.0B20-F 2026-03-20
FY 2022
2022-12-31
$2.1B$423.2M$715.3M$730.7M$1.9B$2.1B20-F 2025-03-31
FY 2021
2021-12-31
$2.3B$512.6M$639.0M$880.5M$1.9B$2.3B20-F 2024-03-11
FY 2020
2020-12-31
$1.9B$359.2M$457.8M$598.0M$1.9B$1.9B20-F 2023-03-13
FY 2019
2019-12-31
$1.5B-$41.5M$330.8M$623.6M$1.7B$1.5B20-F 2022-03-14
FY 2018
2018-12-31
$1.5B$190.4M$359.5M$1.2B$2.2B$1.5B20-F 2021-03-05

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FINAL PROSPECTUS SUPPLEMENT
424B52009-09-25
Latest annual report20-F2026-03-20
Latest quarterly / interim6-K2026-11-06

Source: SEC EDGAR submissions feed, 513 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.9%
1 month+9.8%
3 months+15.4%
Year to date+10.9%
1 year+11.7%
From 52-week high-10.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
RGENRepligen Corporation$162.78-2.99%$10.4B
KYMRKymera Therapeutics Inc.$125.85-1.35%$10.7B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B
TECHBio-Techne Corp$72.79-0.01%$11.4B
KRYSKrystal Biotech Inc.$297.90-2.40%$8.8B
CGONCG Oncology Inc.$84.78+13.95%$7.6B
TWSTTwist Bioscience Corporation$105.04-5.88%$7.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier